GEN Exclusives

More »

GEN News Highlights

More »
Mar 5, 2012

Agenus Expands QS-21 Adjuvant License with GSK for $9M

  • GlaxoSmithKline (GSK) is paying Agenus $9 million to include additional rights to the firms’ existing agreement to use Agenus’ QS-21 Stimulon® adjuvant. Besides amending their license and manufacturing terms, Agenus has granted GSK the first right to negotiate for the purchase of Agenus or certain of its assets. The first right to negotiate will expire after five years.

    The $9 million is a nonrefundable payment of which $2.5 million is creditable against future manufacturing technology transfer royalty payments. The agreement also includes royalty payments for an undisclosed indication upon commercialization of a vaccine product.

    QS-21 Stimulon is designed to strengthen the body's immune response to a vaccine's antigen. QS-21 is being studied in clinical trials for 15 vaccine programs, according to Agenus. It is reportedly being used in the development of vaccine formulations across a variety of prophylactic and therapeutic vaccines.

    Development programs with QS-21 include GSK's Phase III programs RTS,S for malaria, MAGE-A3 immunotherapeutics for resected melanoma and resected non-small-cell lung cancer, and Herpes Zoster for shingles, as well as GSK’s Phase II ACC-001 for Alzheimer disease. Agenus’ pipeline includes Phase II Prophage Series G-100 for newly diagnosed glioma, Prophage Series G-200 for recurrent glioma, and HerpV for genital herpes.

    Licensees of QS-21 include GSK, Janssen Alzheimer Immunotherapy, and Integrated Biotherapeutics. Agenus is generally entitled to receive milestone payments as QS-21-containing programs advance as well as royalties on sales of products.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »